← Nano Nuclear Energy Inc. Common Stock overview

Nano Nuclear Energy Inc. Common Stock vs BWX: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Nano Nuclear Energy Inc. Common Stock (NNE)

Q3 2026
▲3▼1

Nano Nuclear Advances on Regulatory and Contract Wins, But No Revenue Yet

  • NRC Accepts KRONOS Construction Permit Application The U.S. Nuclear Regulatory Commission formally accepted Nano Nuclear's construction permit application for its KRONOS microreactor. This is a key regulatory step that could lead to a permit by late 2027. It boosts investor confidence because it shows real progress toward building a commercial reactor, though the reactor won't operate until the 2030s.

    This is a major regulatory milestone that directly advances the company's path to commercialization.

  • Air Force Research Contract for KRONOS MMR Nano Nuclear won a research contract with AFWERX, the Air Force's innovation arm, to study its KRONOS MMR energy system for military energy needs. The stock jumped about 10% on the news. While it's not a reactor sale, it adds credibility and potential future demand from the defense sector.

    This new contract provides external validation and opens a potential new customer channel.

  • Acquisition of Secured Transportation Services Nano Nuclear acquired Secured Transportation Services for $13 million, a profitable company that transports nuclear and radioactive materials. This gives Nano its first revenue stream and expands its nuclear ecosystem. It also leverages Nano's strong cash position of $569 million.

    This acquisition provides immediate revenue and strategic vertical integration.

  • Still Pre-Revenue, Stock Down 70% from High An article highlighted that Nano Nuclear, like Oklo and NuScale, has no revenue and is pre-commercial. The stock is about 70% below its 52-week high. While the company has cash, the lack of sales and long timeline to commercialization weigh on the stock.

    This points out the key risk: no revenue and a beaten-down share price.

July 2026
▲3▼1

Nano Nuclear Advances on Regulatory and Contract Wins, But No Revenue Yet

  • NRC Accepts KRONOS Construction Permit Application The U.S. Nuclear Regulatory Commission formally accepted Nano Nuclear's construction permit application for its KRONOS microreactor. This is a key regulatory step that could lead to a permit by late 2027. It boosts investor confidence because it shows real progress toward building a commercial reactor, though the reactor won't operate until the 2030s.

    This is a major regulatory milestone that directly advances the company's path to commercialization.

  • Air Force Research Contract for KRONOS MMR Nano Nuclear won a research contract with AFWERX, the Air Force's innovation arm, to study its KRONOS MMR energy system for military energy needs. The stock jumped about 10% on the news. While it's not a reactor sale, it adds credibility and potential future demand from the defense sector.

    This new contract provides external validation and opens a potential new customer channel.

  • Acquisition of Secured Transportation Services Nano Nuclear acquired Secured Transportation Services for $13 million, a profitable company that transports nuclear and radioactive materials. This gives Nano its first revenue stream and expands its nuclear ecosystem. It also leverages Nano's strong cash position of $569 million.

    This acquisition provides immediate revenue and strategic vertical integration.

  • Still Pre-Revenue, Stock Down 70% from High An article highlighted that Nano Nuclear, like Oklo and NuScale, has no revenue and is pre-commercial. The stock is about 70% below its 52-week high. While the company has cash, the lack of sales and long timeline to commercialization weigh on the stock.

    This points out the key risk: no revenue and a beaten-down share price.

Latest
▲3▼1

Nano Nuclear Advances on Regulatory and Contract Wins, But No Revenue Yet

  • NRC Accepts KRONOS Construction Permit Application The U.S. Nuclear Regulatory Commission formally accepted Nano Nuclear's construction permit application for its KRONOS microreactor. This is a key regulatory step that could lead to a permit by late 2027. It boosts investor confidence because it shows real progress toward building a commercial reactor, though the reactor won't operate until the 2030s.

    This is a major regulatory milestone that directly advances the company's path to commercialization.

  • Air Force Research Contract for KRONOS MMR Nano Nuclear won a research contract with AFWERX, the Air Force's innovation arm, to study its KRONOS MMR energy system for military energy needs. The stock jumped about 10% on the news. While it's not a reactor sale, it adds credibility and potential future demand from the defense sector.

    This new contract provides external validation and opens a potential new customer channel.

  • Acquisition of Secured Transportation Services Nano Nuclear acquired Secured Transportation Services for $13 million, a profitable company that transports nuclear and radioactive materials. This gives Nano its first revenue stream and expands its nuclear ecosystem. It also leverages Nano's strong cash position of $569 million.

    This acquisition provides immediate revenue and strategic vertical integration.

  • Still Pre-Revenue, Stock Down 70% from High An article highlighted that Nano Nuclear, like Oklo and NuScale, has no revenue and is pre-commercial. The stock is about 70% below its 52-week high. While the company has cash, the lack of sales and long timeline to commercialization weigh on the stock.

    This points out the key risk: no revenue and a beaten-down share price.

BWX Technologies Inc (BWXT)

Q3 2026
▲4

BWXT Raises Guidance on Strong Q2 and Saudi Nuclear Deal

  • Saudi Nuclear Pact Opens New Market The U.S. and Saudi Arabia signed a 30-year civilian nuclear deal that favors American companies. BWXT, as a nuclear component and service provider, could win new contracts, boosting future revenue and profit.

    This is a new, major demand driver that expands BWXT's addressable market.

  • Strong Q2 and Raised 2026 Guidance BWXT reported Q2 revenue of $901.6M (up 18%) and EPS of $1.07, beating estimates. It raised full-year EBITDA and EPS guidance, signaling confidence in continued growth.

    This is the core financial update that directly lifts investor expectations and the stock price.

  • Medical Business Sale Sharpens Focus BWXT agreed to sell its medical unit for up to $800M, keeping a minority stake. The proceeds will fund core nuclear defense and commercial power, improving capital allocation and profitability.

    This strategic move frees up capital and refocuses the company on higher-growth areas.

  • Backlog Surges 39.6% to $8.4B BWXT's backlog jumped to $8.40 billion, up 39.6% from last year, driven by strong government and commercial nuclear demand. This provides revenue visibility and supports future growth.

    A record backlog is a key indicator of future sales and earnings power.

August 2026
▲4

BWXT Raises Guidance on Strong Q2 and Saudi Nuclear Deal

  • Saudi Nuclear Pact Opens New Market The U.S. and Saudi Arabia signed a 30-year civilian nuclear deal that favors American companies. BWXT, as a nuclear component and service provider, could win new contracts, boosting future revenue and profit.

    This is a new, major demand driver that expands BWXT's addressable market.

  • Strong Q2 and Raised 2026 Guidance BWXT reported Q2 revenue of $901.6M (up 18%) and EPS of $1.07, beating estimates. It raised full-year EBITDA and EPS guidance, signaling confidence in continued growth.

    This is the core financial update that directly lifts investor expectations and the stock price.

  • Medical Business Sale Sharpens Focus BWXT agreed to sell its medical unit for up to $800M, keeping a minority stake. The proceeds will fund core nuclear defense and commercial power, improving capital allocation and profitability.

    This strategic move frees up capital and refocuses the company on higher-growth areas.

  • Backlog Surges 39.6% to $8.4B BWXT's backlog jumped to $8.40 billion, up 39.6% from last year, driven by strong government and commercial nuclear demand. This provides revenue visibility and supports future growth.

    A record backlog is a key indicator of future sales and earnings power.

Latest
▲4

BWXT Raises Guidance on Strong Q2 and Saudi Nuclear Deal

  • Saudi Nuclear Pact Opens New Market The U.S. and Saudi Arabia signed a 30-year civilian nuclear deal that favors American companies. BWXT, as a nuclear component and service provider, could win new contracts, boosting future revenue and profit.

    This is a new, major demand driver that expands BWXT's addressable market.

  • Strong Q2 and Raised 2026 Guidance BWXT reported Q2 revenue of $901.6M (up 18%) and EPS of $1.07, beating estimates. It raised full-year EBITDA and EPS guidance, signaling confidence in continued growth.

    This is the core financial update that directly lifts investor expectations and the stock price.

  • Medical Business Sale Sharpens Focus BWXT agreed to sell its medical unit for up to $800M, keeping a minority stake. The proceeds will fund core nuclear defense and commercial power, improving capital allocation and profitability.

    This strategic move frees up capital and refocuses the company on higher-growth areas.

  • Backlog Surges 39.6% to $8.4B BWXT's backlog jumped to $8.40 billion, up 39.6% from last year, driven by strong government and commercial nuclear demand. This provides revenue visibility and supports future growth.

    A record backlog is a key indicator of future sales and earnings power.

Q2 2026
▲4

BWXT's nuclear growth accelerates on AI power demand and commercial expansion

  • mPower SMR licensing deal BWXT licensed its mPower small modular reactor technology to Applied Atomics, keeping exclusive manufacturing rights and royalties. This opens a new revenue stream from future SMR deployments, driven by rising electricity demand from data centers.

    New licensing agreement directly adds a potential high-margin revenue stream and validates BWXT's technology.

  • Commercial revenue surges 121% BWXT's commercial nuclear segment revenue jumped 121% in Q1 2026 to $283.6 million, with backlog at $1.72 billion. This shows strong demand for its commercial nuclear components and services, boosting growth prospects.

    Concrete financial data reveals a major growth driver that is new and directly impacts future earnings.

  • Analyst upgrades and price target hikes Seaport Research and Deutsche Bank upgraded BWXT to Buy with price targets of $245 and $255, citing strong results, higher guidance, and the Precision Components acquisition. Upgrades can attract more investors and lift the stock price.

    New analyst actions reflect improving sentiment and can influence short-term demand for the stock.

  • Long-term material supply agreement with ATI BWXT signed a supply deal with ATI through fiscal 2030 for specialized materials used in naval nuclear propulsion. This secures critical inputs for its Navy programs, reducing supply risk and supporting steady production.

    New agreement ensures supply chain stability for a key revenue segment, which is important for long-term growth.

June 2026
▲4

BWXT's nuclear growth accelerates on AI power demand and commercial expansion

  • mPower SMR licensing deal BWXT licensed its mPower small modular reactor technology to Applied Atomics, keeping exclusive manufacturing rights and royalties. This opens a new revenue stream from future SMR deployments, driven by rising electricity demand from data centers.

    New licensing agreement directly adds a potential high-margin revenue stream and validates BWXT's technology.

  • Commercial revenue surges 121% BWXT's commercial nuclear segment revenue jumped 121% in Q1 2026 to $283.6 million, with backlog at $1.72 billion. This shows strong demand for its commercial nuclear components and services, boosting growth prospects.

    Concrete financial data reveals a major growth driver that is new and directly impacts future earnings.

  • Analyst upgrades and price target hikes Seaport Research and Deutsche Bank upgraded BWXT to Buy with price targets of $245 and $255, citing strong results, higher guidance, and the Precision Components acquisition. Upgrades can attract more investors and lift the stock price.

    New analyst actions reflect improving sentiment and can influence short-term demand for the stock.

  • Long-term material supply agreement with ATI BWXT signed a supply deal with ATI through fiscal 2030 for specialized materials used in naval nuclear propulsion. This secures critical inputs for its Navy programs, reducing supply risk and supporting steady production.

    New agreement ensures supply chain stability for a key revenue segment, which is important for long-term growth.

▲4

BWXT's nuclear growth accelerates on AI power demand and commercial expansion

  • mPower SMR licensing deal BWXT licensed its mPower small modular reactor technology to Applied Atomics, keeping exclusive manufacturing rights and royalties. This opens a new revenue stream from future SMR deployments, driven by rising electricity demand from data centers.

    New licensing agreement directly adds a potential high-margin revenue stream and validates BWXT's technology.

  • Commercial revenue surges 121% BWXT's commercial nuclear segment revenue jumped 121% in Q1 2026 to $283.6 million, with backlog at $1.72 billion. This shows strong demand for its commercial nuclear components and services, boosting growth prospects.

    Concrete financial data reveals a major growth driver that is new and directly impacts future earnings.

  • Analyst upgrades and price target hikes Seaport Research and Deutsche Bank upgraded BWXT to Buy with price targets of $245 and $255, citing strong results, higher guidance, and the Precision Components acquisition. Upgrades can attract more investors and lift the stock price.

    New analyst actions reflect improving sentiment and can influence short-term demand for the stock.

  • Long-term material supply agreement with ATI BWXT signed a supply deal with ATI through fiscal 2030 for specialized materials used in naval nuclear propulsion. This secures critical inputs for its Navy programs, reducing supply risk and supporting steady production.

    New agreement ensures supply chain stability for a key revenue segment, which is important for long-term growth.

© 2026 MarketIVWhy